Contents
Editor’s Letter
Fourth and final issue of GaBI Journal’s sixth volume
Letters to the Editor
Clear naming, traceability of biological medicines will protect patients
Comment on the non-biological complex drugs paper
Commentary
Global policies on pharmacy-mediated substitution of biosimilars: a summary
Original Research
Review Article
Major lessons learned from Zarxio’s US launch: the start of a biosimilar revolution
Perspective
40th anniversary of essential medicines: a loud call for improving its access
Guidelines
Biosimilars in Germany: guidance of the Drug Commission of the German Medical Association
Special Report
Building stakeholder confidence in biosimilar medicines through evidence-based information sharing
USA and Europe differ in interchangeability of biosimilars
Meeting Report
Perspectives on the future of pegfilgrastim biosimilars
Abstracted Scientific Content
A comparison of European and US generic drug markets